It was certainly never going to be case that the MHRA would abdicate their regulatory responsibility, and place the nod of approval in the hands of commercially incentivised entities, nor base it solely on the printed opinion in an online magazine article.
As you can imagine, the level of forensic auditing of a company wishing to supply cancer treatments to the NHS, at the premium demanded, requires a damn sight more than just vested interest hearsay about how great it is.
With that in mind, some here need to wake the F up about the likelihood of getting an MAA granted, and the chances of NICE reimbursements.
There is also the more abstract concept of a supplier's fitness, both ethically and financially, to operate in partnership with the NHS, who's primary role and purpose, is to safe guard both the physical and mental well being of it's most vulnerable patients.
Under pinning that, is the provision of treatment at a price point, that will not impact the ability of our healthcare system to treat the majority.
Market Data 
Markets 
AI
